GlassScriptPhysician profile
Albert Jang
NPI 1003376468
$6,608.24
in general payments reported to CMS, 2019-2025
39 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $347 · 2023: $1,808 · 2024: $2,856 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,830 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,829.80 |
| Education | $292.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.64 | 2023-2025 | Lynparza, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $544.95 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $499.08 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $469.15 | 2023-2025 | Fruzaqla, Iclusig, Alunbrig |
| Dendreon Pharmaceuticals LLC | $339.40 | 2021-2022 | |
| Janssen Biotech, INC. | $338.44 | 2024-2025 | Rybrevant, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $330.66 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Beone Medicines USA, INC. | $295.86 | 2025 | Brukinsa, Tevimbra |
| Gilead Sciences, INC. | $266.12 | 2022-2024 | Trodelvy |
| Seagen INC. | $252.05 | 2023 | Tukysa |
| Daiichi Sankyo INC. | $230.44 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $216.85 | 2023-2025 | |
| Incyte Corporation | $168.51 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $165.07 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $146.77 | 2023-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $133.64 | 2025 | Cabometyx |
| Amgen INC. | $129.11 | 2024 | |
| Beigene USA, INC. | $125.00 | 2025 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $118.30 | 2024 | |
| Emd Serono, INC. | $114.57 | 2023 | Bavencio |
| Genzyme Corporation | $114.29 | 2023-2025 | |
| Foundation Medicine, INC. | $106.16 | 2023 | |
| Glaxosmithkline, LLC. | $89.27 | 2024 | Ojjaara |
| Abbvie INC. | $88.88 | 2024-2025 | |
| Celgene Corporation | $70.39 | 2024-2025 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $70.03 | 2024-2025 | |
| Tempus Ai, INC | $69.70 | 2024 | |
| Gt Medical Technologies, INC | $60.68 | 2023 | Gammatile |
| Medexus Pharma, INC. | $60.68 | 2023 | Gleolan |
| Genmab U.S., INC. | $58.76 | 2023-2024 | Tivdak, Epkinly |
| Astellas Pharma US INC | $55.82 | 2024 | Vyloy |
| Blueprint Medicines Corporation | $50.81 | 2024-2025 | Ayvakit |
| Sobi, INC | $42.45 | 2024-2025 | |
| Morphosys, US INC. | $33.94 | 2023 | Monjuvi |
| Lilly USA, LLC | $26.60 | 2025 | Jaypirca, Verzenio |
| Agios Pharmaceuticals, INC. | $24.67 | 2025 | Pyrukynd |
| Kite Pharma, INC. | $16.45 | 2023 | Yescarta |
| Genentech USA, INC. | $14.63 | 2025 | Tecentriq |
| Verity Pharmaceuticals INC. | $13.42 | 2024 | Trelstar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Jang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.